The down-scheduling of several triptans in 2021 has helped improve patient access to migraine-specific treatments.1 However, pharmacists may still be unclear on what the regulatory and clinical considerations are for S3 triptans. Are they only for emergency supply? If so, why down-schedule when an emergency supply applies to prescription medicines?2 "Ran out of my
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.